Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice

Vaccine

Volumn 25, Issue 4, 2007, Pages 612-620

  Kreijtz, J H C M ^a   Bodewes, R ^a   van Amerongen, G ^a   Kuiken, T ^a   Fouchier, R A M ^a   Osterhaus, A D M E ^a   Rimmelzwaan, G F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cross protection; CTL; Influenza

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNITY; IMMUNOHISTOCHEMISTRY; INFLUENZA; INFLUENZA VIRUS A; LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS STRAIN; VIRUS TITRATION;

ANIMALS; FEMALE; IMMUNOHISTOCHEMISTRY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; LUNG; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; SPECIFIC PATHOGEN-FREE ORGANISMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 33845205893     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.08.036     Document Type: Article

References (51)

1. Claas E.C., Osterhaus A.D., van Beek R., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351 9101 (1998) 472-477
2. de Jong J.C., Claas E.C., Osterhaus A.D., Webster R.G., and Lim W.L. A pandemic warning?. Nature 389 6651 (1997) 554
3. Subbarao K., Klimov A., Katz J., et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279 5349 (1998) 393-396
4. Beigel J.H., Farrar J., Han A.M., et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 353 13 (2005) 1374-1385
5. Tran T.H., Nguyen T.L., Nguyen T.D., et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350 12 (2004) 1179-1188
6. WHO. WHO disease alert 2006. Confirmed human cases of avian influenza H5N1. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_04_19/en/index.html in accessed April 12, 2006, 2006.
7. WHO. WHO intercountry-consultation. Influenza A/H5N1 in humans in Asia. http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_7/en/. Manila, Philippines, 2006.
8. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005;11(10):1515-21.
9. McMichael A.J., Gotch F.M., Noble G.R., and Beare P.A. Cytotoxic T-cell immunity to influenza. N Engl J Med 309 1 (1983) 13-17
10. McMichael A.J., Michie C.A., Gotch F.M., Smith G.L., and Moss B. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 67 Pt 4 (1986) 719-726
11. Townsend A.R., Rothbard J., Gotch F.M., Bahadur G., Wraith D., and McMichael A.J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44 6 (1986) 959-968
12. Schulman J.L., and Kilbourne E.D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J Bacteriol 89 (1965) 170-174
13. Epstein S.L., Lo C.Y., Misplon J.A., et al. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. J Immunol 158 3 (1997) 1222-1230
14. Benton K.A., Misplon J.A., Lo C.Y., Brutkiewicz R.R., Prasad S.A., and Epstein S.L. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. J Immunol 166 12 (2001) 7437-7445
15. Nguyen H.H., Moldoveanu Z., Novak M.J., et al. Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology 254 1 (1999) 50-60
16. Nguyen H.H., van Ginkel F.W., Vu H.L., Novak M.J., McGhee J.R., and Mestecky J. Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice. J Virol 74 12 (2000) 5495-5501
17. Nguyen H.H., van Ginkel F.W., Vu H.L., McGhee J.R., and Mestecky J. Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis 183 3 (2001) 368-376
18. Jameson J., Cruz J., Terajima M., and Ennis F.A. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162 12 (1999) 7578-7583
19. Jameson J., Cruz J., and Ennis F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol 72 11 (1998) 8682-8689
20. Kees U., and Krammer P.H. Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. J Exp Med 159 2 (1984) 365-377
21. Liang S., Mozdzanowska K., Palladino G., and Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 152 4 (1994) 1653-1661
22. O'Neill E., Krauss S.L., Riberdy J.M., Webster R.G., and Woodland D.L. Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 81 Pt 11 (2000) 2689-2696
23. Saelens X., Vanlandschoot P., Martinet W., et al. Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin. Eur J Biochem 260 1 (1999) 166-175
24. Coleclough C., Sealy R., Surman S., Marshall D.R., and Hurwitz J.L. Respiratory vaccination of mice against influenza virus: dissection of T- and B-cell priming functions. Scand J Immunol 62 Suppl 1 (2005) 73-83
25. Ulmer J.B., Fu T.M., Deck R.R., et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 72 7 (1998) 5648-5653
26. Bender B.S., Croghan T., Zhang L., and Small Jr. P.A. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 175 4 (1992) 1143-1145
27. Eichelberger M., Allan W., Zijlstra M., Jaenisch R., and Doherty P.C. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med 174 4 (1991) 875-880
28. Cassetti M.C., Couch R., Wood J., and Pervikov Y. Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004. Vaccine 23 13 (2005) 1529-1533
29. Cassetti M.C., Katz J.M., and Wood J. Report of a consultation on role of immunological assays to evaluate efficacy of influenza vaccines. Initiative for Vaccine Research and Global Influenza Programme, World Health Organization, Geneva, Switzerland, 25 January 2005. Vaccine 24 5 (2006) 541-543
30. Doherty P.C., Biddison W.E., Bennink J.R., and Knowles B.B. Cytotoxic T-cell responses in mice infected with influenza and vaccinia viruses vary in magnitude with H-2 genotype. J Exp Med 148 2 (1978) 534-543
31. Vitiello A., Yuan L., Chesnut R.W., et al. Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J Immunol 157 12 (1996) 5555-5562
32. Belz G.T., Xie W., Altman J.D., and Doherty P.C. A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge. J Virol 74 8 (2000) 3486-3493
33. Baez M., Palese P., and Kilbourne E.D. Gene composition of high-yielding influenza vaccine strains obtained by recombination. J Infect Dis 141 3 (1980) 362-365
34. Kilbourne E.D. Future influenza vaccines and the use of genetic recombinants. Bull World Health Org 41 3 (1969) 643-645
35. Haanen J.B., Wolkers M.C., Kruisbeek A.M., and Schumacher T.N. Selective expansion of cross-reactive CD8(+) memory T cells by viral variants. J Exp Med 190 9 (1999) 1319-1328
36. Turner S.J., Kedzierska K., La Gruta N.L., Webby R., and Doherty P.C. Characterization of CD8+ T cell repertoire diversity and persistence in the influenza A virus model of localized, transient infection. Semin Immunol 16 3 (2004) 179-184
37. Rimmelzwaan G.F., Baars M., Claas E.C., and Osterhaus A.D. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Meth 74 1 (1998) 57-66
38. Palmer D., et al. Haemagglutination inhibition test. Advanced laboratory techniques for influenza diagnosis. Procedural Guide (1975), US Department of Health ED, Atlanta 25-62
39. Frank A.L., Puck J., Hughes B.J., and Cate T.R. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol 12 3 (1980) 426-432
40. Belz G.T., Xie W., and Doherty P.C. Diversity of epitope and cytokine profiles for primary and secondary influenza a virus-specific CD8+ T cell responses. J Immunol 166 7 (2001) 4627-4633
41. Ulmer J.B., Deck R.R., DeWitt C.M., Friedman A., Donnelly J.J., and Liu M.A. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 12 16 (1994) 1541-1544
42. Flynn K.J., Belz G.T., Altman J.D., Ahmed R., Woodland D.L., and Doherty P.C. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 8 6 (1998) 683-691
43. Woodland D.L., and Scott I. T cell memory in the lung airways. Proc Am Thorac Soc 2 2 (2005) 126-131
44. Seo S.H., Peiris M., and Webster R.G. Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8(+) T cells expressing gamma interferon. J Virol 76 10 (2002) 4886-4890
45. Liu W., Li H., and Chen Y.H. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol 35 2 (2003) 141-146
46. Jegerlehner A., Schmitz N., Storni T., and Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172 9 (2004) 5598-5605
47. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., and Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5 10 (1999) 1157-1163
48. Tamura S., Tanimoto T., and Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 58 4 (2005) 195-207
49. Liu W., Zou P., and Chen Y.H. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 93 2-3 (2004) 131-136
50. Yuen K.Y., Chan P.K., Peiris M., et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351 9101 (1998) 467-471
51. Chotpitayasunondh T., Ungchusak K., Hanshaoworakul W., et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 11 2 (2005) 201-209